Literature DB >> 33907876

Human risk assessment of di-isobutyl phthalate through the application of a developed physiologically based pharmacokinetic model of di-isobutyl phthalate and its major metabolite mono-isobutyl phthalate.

Seung-Hyun Jeong1, Ji-Hun Jang1, Hea-Young Cho2, Yong-Bok Lee3.   

Abstract

Di-isobutyl phthalate (DiBP) is a substance used in the production of objects frequently used in human life. Mono-isobutyl phthalate (MiBP), a major in vivo metabolite of DiBP, is a biomarker for DiBP exposure assessment. Therefore, risk assessment studies on DiBP and MiBP, which have not yet been reported in detail, are needed. The aim of this study was to develop and evaluate a physiologically based pharmacokinetic (PBPK) model for DiBP and MiBP in rats and extend this to human risk assessment based on human exposure. Pharmacokinetic studies were performed in male rats following the administration of 5-100 mg/kg DiBP, and these results were used for the development and validation of the PBPK model. In addition, the previous pharmacokinetic results in female rats following DiBP administration and the pharmacokinetic results in both males and females according to multiple exposures to DiBP were used to develop and validate the PBPK model. The metabolism of DiBP to MiBP in the body was very significant and rapid, and the biodistribution of MiBP was broad and major. Furthermore, the amount of MiBP in the body showed a correlation with DiBP exposure, and from this, a PBPK model was developed to evaluate the external exposure of DiBP from the internal exposure of MiBP. The predicted rat plasma, urine, fecal, and tissue concentrations using the developed PBPK model fitted well with the observed values. The established PBPK model for rats was extrapolated to a human PBPK model of DiBP and MiBP based on human physiological parameters and allometric scaling. The reference dose of 0.512 mg/kg/day of DiBP and external doses of 6.14-280.90 μg/kg/day DiBP for human risk assessment were estimated using Korean biomonitoring values. Valuable insight and approaches to assessing human health risks associated with DiBP exposure were provided by this study.

Entities:  

Keywords:  Di-isobutyl phthalate; External exposure; Human risk assessment; Mono-isobutyl phthalate; Physiologically based pharmacokinetic model

Mesh:

Substances:

Year:  2021        PMID: 33907876     DOI: 10.1007/s00204-021-03057-5

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  4 in total

1.  Age and sex differences in childhood and adulthood obesity association with phthalates: analyses of NHANES 2007-2010.

Authors:  Melanie C Buser; H Edward Murray; Franco Scinicariello
Journal:  Int J Hyg Environ Health       Date:  2014-03-05       Impact factor: 5.840

2.  Development and application of simple pharmacokinetic models to study human exposure to di-n-butyl phthalate (DnBP) and diisobutyl phthalate (DiBP).

Authors:  Matthew Lorber; Holger M Koch
Journal:  Environ Int       Date:  2013-08-15       Impact factor: 9.621

3.  Diisobutyl phthalate has comparable anti-androgenic effects to di-n-butyl phthalate in fetal rat testis.

Authors:  Julie Borch; Marta Axelstad; Anne Marie Vinggaard; Majken Dalgaard
Journal:  Toxicol Lett       Date:  2006-02-02       Impact factor: 4.372

4.  Age and Gender Differences in Urinary Levels of Eleven Phthalate Metabolites in General Taiwanese Population after a DEHP Episode.

Authors:  Po-Chin Huang; Chih-Hsin Tsai; Wei-Yen Liang; Sih-Syuan Li; Wen-Harn Pan; Hung-Che Chiang
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

  4 in total
  1 in total

1.  Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically based pharmacokinetic (PBPK) modeling: analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Hea-Young Cho; Yong-Bok Lee
Journal:  Arch Toxicol       Date:  2022-06-20       Impact factor: 6.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.